Profilo
Dr. Harry Kopelman, MD, is Scientific Advisor at Easton Capital Investment Group.
Dr. Kopelman is a graduate of the Georgetown University School of Medicine, Washington, D.C.
(1980).
He completed his internship/residency at North Carolina Memorial Hospital/University of North Carolina, Chapel Hill (1983).
His fellowship in Cardiovascular Disease and Cardiac Electrophysiology was at the Vanderbilt University School of Medicine in Nashville, TN (1985).
Precedenti posizioni note di Harry Kopelman
| Società | Posizione | Fine |
|---|---|---|
Arterain Medical, Inc.
Arterain Medical, Inc. Medical SpecialtiesHealth Technology Develops medical devices to treat large vessel acute ischemic strokes | Direttore/Membro del Consiglio | - |
Easton Capital Investment Group
Easton Capital Investment Group Investment ManagersFinance Easton invests in all segments of the healthcare industry, including biopharmaceuticals, drug delivery, medical devices and healthcare services. The firm is stage-agnostic and considers opportunities from early-stage venture capital to later-stage growth capital with investment size ranging from $0.05 - $10 million. They are generally not a seed-stage investor. | Corporate Officer/Principal | - |
Formazione di Harry Kopelman
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Arterain Medical, Inc.
Arterain Medical, Inc. Medical SpecialtiesHealth Technology Develops medical devices to treat large vessel acute ischemic strokes | Health Technology |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Easton Capital Investment Group
Easton Capital Investment Group Investment ManagersFinance Easton invests in all segments of the healthcare industry, including biopharmaceuticals, drug delivery, medical devices and healthcare services. The firm is stage-agnostic and considers opportunities from early-stage venture capital to later-stage growth capital with investment size ranging from $0.05 - $10 million. They are generally not a seed-stage investor. | Finance |
















